Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia - Takeaways - MDSpire

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

Near vision improvements were demonstrated within 30 minutes and lasted up to 10 hours in clinical trials.

  • July 8, 2025

  • 2 min

Share

  • 1

    Lenz Therapeutics received FDA approval for Vizz, an eye drop solution for treating presbyopia in adults.

  • 2

    Vizz improves near vision within 30 minutes and effects last up to 10 hours.

  • 3

    The treatment works by contracting the iris sphincter muscle to create a pinhole effect, enhancing depth of focus.

  • 4

    Clinical trials CLARITY 1, 2, and 3 demonstrated Vizz's safety and efficacy with mild, transient adverse events.

  • 5

    Commercial availability of Vizz is expected by mid-Q4 2025, with samples anticipated as early as October 2025.

Original Source(s)

Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia

  • July 8, 2025

Related Content

Fast Forward to the Future: Contact Lens Microfluidics

Everest Expands Ophthalmology Portfolio in China

Everest Medicines acquires rights to presbyopia eye drop

  • June 15, 2026

  • 2 min
Cataract Surgeons Gain a New Lens Tool

An extended depth of focus intraocular lens approved by the FDA is designed to improve visual range while maintaining contrast sensitivity in cataract surgery.